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There was indeed no washout period of enalapril; how-
ever, only 27% of patients were on enalapril at entry [29%
in the MMF group and 23% in the placebo group; P =
0.7867 (chi-square)]. The lack of impact of MMF on renal
function noted in our study is difficult to explain by this
phenomenon.
Because of small sample size, the data were ana-
lyzed using nonparametric statistics (Wilcoxon rank sum
test, chi-square test, linear mixed models), applicable to
both normal and non-normal distributed sample data
[2, 3].
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Hepatic iron in hemodialysis
patients
To the Editors: Canavese et al [1] reported that hepatic
iron overload is common in hemodialysis patients, and
suggested a reevaluation of acceptable iron parameters.
This was a well-designed study, and the work is an impor-
tant contribution to our knowledge on iron storage in this
patient population. It should be noted, however, that it
may not be reasonable to extrapolate these results to the
general hemodialysis population. To properly answer the
question of how prevalent iron overload is in hemodial-
ysis patients, an unselected group of patients should be
studied. This was not true of Canavese’s cohort. Thirty
out of 40 subjects (75%) had to discontinue 15 months
of continuous intravenous iron therapy due to serum fer-
ritin >500 ng/mL. Therefore, there was a strong selection
bias towards an iron-overloaded subpopulation.
It should be noted that the major finding of this study,
that many patients on hemodialysis had mild to moderate
hepatic iron “overload,” is not a new finding. More than
20 years ago, Ali et al [2] and Gokal et al [3] performed au-
topsy studies and found excess hepatic iron in hemodialy-
sis patients. In contrast to Canavese’s study, these authors
had access to hepatic tissue, allowing them to determine if
the excess iron was found in association with tissue dam-
age. Ali found significant iron excess in the livers of 48%
of subjects. Importantly, no liver pathology or damage
was found, even in cases of severe iron overload. Indeed,
anecdotally, there does not appear to be any excess preva-
lence of cirrhosis among hemodialysis patients. The fact
that hepatic tissue damage does not seem to coexist with
hepatic iron overload suggests that hepatic iron excess,
as found by Ali, Gokal, and Canavese, may simply be a
reflection of shifted iron pools. Indeed, an elevated serum
ferritin (iron storage marker) concurrent with low or nor-
mal transferrin saturation (iron circulation marker) is a
frequent finding in hemodialysis patients, consistent with
a shift of iron pools away from the circulation and into
storage tissues. Inflammation may be the key central link
and driver of this process. Recently, a strong association
was found between measures of inflammation and serum
ferritin [4, 5]. The phenomenon may best be understood
as inflammation leading to a state of reticuloendothelial
blockade that causes hemodialysis patients to have in-
creased hepatic storage of poorly mobile iron.
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The impact of serum uric acid
on cardiovascular outcomes in
the LIFE study
To the Editor: The analysis of the role of serum uric
acid (SUA) levels in the Losartan In tervention for End-
point reduction in hypertension study (LIFE) study is of
